Aligos Therapeutics Inc ALGS.OQ reported a quarterly adjusted loss of $3.07 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-10.25. The mean expectation of three analysts for the quarter was for a loss of $2.16 per share. Wall Street expected results to range from $-4.40 to 45 cents per share.
Revenue fell 60.8% to $1.27 million from a year ago; analysts expected $333.33 thousand.
Aligos Therapeutics Inc's reported EPS for the quarter was a loss of $3.07.
The company reported a quarterly loss of $19.26 million.
Aligos Therapeutics Inc shares had risen by 8.0% this quarter and lost 43.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 115.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Aligos Therapeutics Inc is $75.00
This summary was machine generated from LSEG data November 7 at 02:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -2.16 | -3.07 | Missed |
Jun. 30 2024 | -4.00 | 0.80 | Beat |
Mar. 31 2024 | -4.75 | -5.50 | Missed |
Dec. 31 2023 | -6.75 | -5.50 | Beat |
Comments